• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.

作者信息

Stienen Susan, Ferreira João Pedro, Pitt Bertram, Cleland John G, Pellicori Pierpaolo, Girerd Nicolas, Rossignol Patrick, Zannad Faiez

机构信息

Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERM U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.

Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

出版信息

Eur J Heart Fail. 2020 May;22(5):901-903. doi: 10.1002/ejhf.1812. Epub 2020 Apr 3.

DOI:10.1002/ejhf.1812
PMID:32243646
Abstract
摘要

相似文献

1
Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.依普利酮可预防心肌梗死后合并左心室功能障碍和/或心力衰竭时血清I型前胶原羧基末端前肽的升高。
Eur J Heart Fail. 2020 May;22(5):901-903. doi: 10.1002/ejhf.1812. Epub 2020 Apr 3.
2
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.急性心肌梗死合并左心室功能障碍和心力衰竭患者的细胞外心脏基质生物标志物：依普利酮急性心肌梗死后心力衰竭疗效和生存研究（EPHESUS）的见解
Circulation. 2009 May 12;119(18):2471-9. doi: 10.1161/CIRCULATIONAHA.108.809194. Epub 2009 Apr 27.
3
Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction.急性心肌梗死后心力衰竭和左心室收缩功能障碍的管理
Clin Cardiol. 2005 Jan;28(1):1-2. doi: 10.1002/clc.4960280102.
4
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.依普利酮，一种选择性醛固酮阻滞剂，用于心肌梗死后左心室功能不全的患者。
N Engl J Med. 2003 Apr 3;348(14):1309-21. doi: 10.1056/NEJMoa030207. Epub 2003 Mar 31.
5
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.随机、双盲、多中心、安慰剂对照研究，评估醛固酮拮抗剂依普利酮对伴有左心室收缩功能障碍的轻至中度心力衰竭患者心室重构的影响。
Circ Heart Fail. 2010 May;3(3):347-53. doi: 10.1161/CIRCHEARTFAILURE.109.906909. Epub 2010 Mar 18.
6
Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.抗纤维化反应对醛固酮受体拮抗剂治疗的影响因素：来自依普利酮治疗急性心肌梗死后心力衰竭疗效和生存研究（EPHESUS）和早期依普利酮治疗急性 ST 段抬高型心肌梗死无心力衰竭患者（REMINDER）试验的研究结果。
Clin Res Cardiol. 2020 Feb;109(2):194-204. doi: 10.1007/s00392-019-01500-3. Epub 2019 Jun 27.
7
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).依普利酮急性心肌梗死后心力衰竭疗效和生存研究（EPHESUS）中的血清钾与临床结局
Circulation. 2008 Oct 14;118(16):1643-50. doi: 10.1161/CIRCULATIONAHA.108.778811. Epub 2008 Sep 29.
8
Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?急性心肌梗死后合并左心室功能不全时，醛固酮受体拮抗剂依普利酮是否应该使用？
Expert Opin Pharmacother. 2003 Sep;4(9):1605-7. doi: 10.1517/14656566.4.9.1605.
9
Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.依普利酮：急性心肌梗死后左心室收缩功能障碍和心力衰竭应用的综述
Drugs. 2004;64(23):2689-707. doi: 10.2165/00003495-200464230-00005.
10
Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.镁元素改变对心肌梗死合并左心室功能障碍患者的预后相关性：来自 EPHESUS 试验的见解。
Eur Heart J Acute Cardiovasc Care. 2022 Feb 8;11(2):148-159. doi: 10.1093/ehjacc/zuab111.

引用本文的文献

1
Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease.醛固酮靶向治疗：在顽固性高血压和慢性肾脏病中的早期应用
Eur Heart J. 2025 Jul 14;46(27):2618-2642. doi: 10.1093/eurheartj/ehaf225.
2
Circulating collagen type I fragments as specific biomarkers of cardiovascular outcome risk: Where are the opportunities?循环I型胶原片段作为心血管结局风险的特异性生物标志物：机遇何在？
Matrix Biol. 2025 May;137:19-32. doi: 10.1016/j.matbio.2025.03.001. Epub 2025 Mar 2.
3
The Pathobiology of Myocardial Recovery and Remission: From Animal Models to Clinical Observations in Heart Failure Patients.
心肌恢复和缓解的病理生物学：从心力衰竭患者的动物模型到临床观察。
Methodist Debakey Cardiovasc J. 2024 Aug 20;20(4):16-30. doi: 10.14797/mdcvj.1389. eCollection 2024.
4
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.螺内酯对心力衰竭高危人群心血管功能和纤维化标志物的影响：衰老中心血管 'OMICS' 研究（HOMAGE）随机临床试验。
Eur Heart J. 2021 Feb 11;42(6):684-696. doi: 10.1093/eurheartj/ehaa758.